Murex losses continue due to litigation costs:
This article was originally published in Clinica
Canadian company International Murex Technologies reported sales of $50.4 million for the six months ended June 30th, 1996, up 6% on the same period in the previous year. The company's net loss was $1.3 million, compared with $3.2 million last year, which reflects the decreasing legal costs relating to HCV patent litigation against Chiron (see Clinica No 632, p 13). The company expects to return to profitability in 1996. Murex has now begun court proceedings against Abbott for patent infringement of its particle bound binding component immunoassay (see Clinica No 713, p 1).
You may also be interested in...
After urging the US Congress to act on updating Medicare Part D, the Association for Accessible Medicines has welcomed the decision to update Part D by the Centers for Medicare & Medicaid Services of the US Department of Health and Human Services.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”